Updated comprehensive review of BPC-157's IBD-relevant evidence: healing colitis, ulcers, fistulas; NO system interactions; prostaglandin modulation; angiogenesis; and clinical trial progression (PL-10, PLD-116, PL14736, Pliva).
Key findingBPC-157 in IBD clinical trials supported by expanded animal evidence: heals colitis/fistulas/strictures, modulates NO and prostaglandin systems, promo
What the researchers found
BPC-157 in IBD clinical trials supported by expanded animal evidence: heals colitis/fistulas/strictures, modulates NO and prostaglandin systems, promotes angiogenesis, and shows cytoprotection across multiple GI inflammation models — updated pre-clinical support for advancing clinical development.
Why it matters
Relevant for bpc-157, gut-healing, wound-healing.
How the study worked
animal-study study.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2007.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat.
Surgery today, 37(9), 768-77
Citation
Vuksic, Tihomir; Zoricic, Ivan; Brcic, Luka; Sever, Marko; Klicek, Robert; Radic, Bozo; Cesarec, Vedran; Berkopic, Lidija; Keller, Neike; Blagaic, Alenka Boban; Kokic, Neven; Jelic, Ivan; Geber, Juraj; Anic, Tomislav; Seiwerth, Sven; Sikiric, Predrag. (2007). Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat.. Surgery today, 37(9), 768-77.